Loading...
XSHE002262
Market cap3.14bUSD
Jan 17, Last price  
22.64CNY
1D
-0.57%
1Q
-16.02%
Jan 2017
73.32%
IPO
991.02%
Name

Jiangsu Nhwa Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002262 chart
P/E
22.19
P/S
4.63
EPS
1.02
Div Yield, %
0.88%
Shrs. gr., 5y
-0.05%
Rev. gr., 5y
5.21%
Revenues
4.97b
+15.70%
638,844,502695,840,266804,825,180952,499,5601,110,938,9541,300,610,8171,587,499,7321,982,496,3932,236,077,0142,501,358,7492,766,567,6223,017,785,7603,393,676,9553,858,168,5904,149,312,4263,361,303,4723,935,664,2194,298,513,0624,973,504,041
Net income
1.04b
+15.12%
16,823,10016,983,07226,655,71840,699,44454,673,00976,435,323105,647,054139,697,895176,253,603223,271,123258,347,050309,743,047394,634,279524,807,849663,308,783728,821,694797,777,327900,709,3301,036,918,058
CFO
1.05b
+22.01%
8,841,01530,989,08248,550,88646,500,88461,271,78761,791,82381,076,208154,164,158194,332,052160,236,857204,235,003277,141,381452,348,798404,524,742305,972,8551,248,348,649701,117,596861,023,1491,050,545,754
Dividend
May 15, 20240.32 CNY/sh
Earnings
Apr 24, 2025

Profile

Jiangsu Nhwa Pharmaceutical Co., LTD produces and sells central nervous system drugs, and cardiovascular and cerebrovascular drugs in China and internationally. The company offers drugs in the anesthesia, psychiatry, and neurological categories. It also provides APIs in the areas of central nervous system, anesthetic and sedative, and others. The company was founded in 1978 and is headquartered in Xuzhou, China.
URL
https://www.nhwa-group.com/
IPO date
Jul 23, 2008
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,973,504
15.70%
4,298,513
9.22%
Cost of revenue
3,351,576
3,173,753
Unusual Expense (Income)
NOPBT
1,621,928
1,124,760
NOPBT Margin
32.61%
26.17%
Operating Taxes
134,397
109,518
Tax Rate
8.29%
9.74%
NOPAT
1,487,531
1,015,241
Net income
1,036,918
15.12%
900,709
12.90%
Dividends
(201,518)
(201,518)
Dividend yield
0.74%
0.81%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
55,000
50,633
Long-term debt
71,345
84,041
Deferred revenue
53,865
58,048
Other long-term liabilities
66,811
1
Net debt
(3,524,887)
(2,849,541)
Cash flow
Cash from operating activities
1,050,546
861,023
CAPEX
(373,989)
Cash from investing activities
(335,637)
Cash from financing activities
(210,174)
FCF
1,088,892
705,252
Balance
Cash
3,493,946
2,984,214
Long term investments
157,286
Excess cash
3,402,557
2,769,289
Stockholders' equity
5,803,328
5,603,522
Invested Capital
3,165,150
2,822,724
ROIC
49.68%
38.27%
ROCE
24.69%
20.10%
EV
Common stock shares outstanding
1,006,717
1,007,588
Price
27.09
10.35%
24.55
56.87%
Market cap
27,271,952
10.25%
24,736,287
56.87%
EV
23,723,031
21,886,746
EBITDA
1,786,013
1,273,416
EV/EBITDA
13.28
17.19
Interest
4,964
4,947
Interest/NOPBT
0.31%
0.44%